B10 is a glycosylated derivative of betulinic acid with promising activity against glioma cells. Lysosomal cell death pathways appear to be essential for its cytotoxicity. We investigated the influence of hypoxia, nutrient deprivation and current standard therapies on B10 cytotoxicity. The human glioma cell lines LN-308 and LNT-229 were exposed to B10 alone or together with irradiation, temozol...

NF-?B-inducing kinase (NIK) is a key enzyme in the noncanonical NF-?B pathway, of interest treatment variety diseases including cancer. Validation NIK as drug target requires potent and selective inhibitors. The protein contains cysteine residue at position 444 back pocket active site, unique within kinome. Analysis existing inhibitor scaffolds early structure-activity relationships (SARs) led ...

We have shown that activation of nuclear factor-kappa B (NF-kappa B) promotes cell survival and expression of cytokines such as growth-regulated oncogene-alpha, which can modulate angiogenesis, growth, and metastasis of squamous cell carcinoma (SCC). Activation of NF-kappa B and cytoprotective genes in cancer may result from signal-induced phosphorylation and proteasome-dependent degradation of...

Background: Non-Hodgkin’s lymphoma (NHLs) is known as a heterogeneous group of malignant lymphoproliferative disorders. NHLs are classified into B cell and T cell types. Immunophenotypical assessment of the biopsy specimens can help diagnose NHLs.    Methods: In this study, 77 patients with B cell and T cell lymphoma were selected from Shahid Sadoghi hospital during 2010 to 2...

Background For the past 20 years, biologic (b)DMARDs have been main treatment option for children and young people with JIA where an initial conventional-synthetic DMARD has not effective. Since 2021, tofacitinib, a Janus Kinase (JAK) inhibitor become available of JIA. In phase 3 randomised controlled withdrawal design trial, tofacitinib demonstrated superior efficacy over placebo, although onl...